Valuation: Mylan N.V.

Market Cap 21.86B 19.58B 18.01B 16.32B 30.51B 2,076B 31.08B 215B 86.22B 1,092B 82.05B 80.31B 3,444B P/E 2026 *
82.6x
P/E 2027 * 50.9x
Enterprise Value 33.53B 30.03B 27.62B 25.03B 46.79B 3,184B 47.66B 329B 132B 1,675B 126B 123B 5,282B EV / Sales 2026 *
2.27x
EV / Sales 2027 * 2.14x
Free-Float
91.44%
Yield 2026 *
2.62%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 21.86B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +2.07%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 14.78B 13.24B 12.17B 11.03B 20.62B 1,403B 21.01B 145B 58.28B 738B 55.46B 54.28B 2,328B 15.22B 13.63B 12.54B 11.36B 21.24B 1,445B 21.63B 150B 60.03B 760B 57.12B 55.91B 2,398B
Net income 142M 127M 117M 106M 197M 13.44B 201M 1.39B 558M 7.07B 531M 520M 22.29B 298M 267M 246M 223M 416M 28.33B 424M 2.93B 1.18B 14.9B 1.12B 1.1B 47B
Net Debt 11.67B 10.45B 9.61B 8.71B 16.28B 1,108B 16.59B 115B 46.02B 583B 43.79B 42.86B 1,838B 10.76B 9.64B 8.87B 8.03B 15.02B 1,022B 15.3B 106B 42.45B 538B 40.39B 39.53B 1,695B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Mylan N.V.